SHR2554 + SHR-A1904

SHR2554 + SHR-A1904 is a combination of two investigational anti-cancer agents developed by Jiangsu Hengrui Medicine for the treatment of advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma. **SHR2554** is a small molecule inhibitor of Enhancer of Zeste Homolog 2 (EZH2), an epigenetic modulator implicated in tumorigenesis by promoting histone methylation and gene silencing. **SHR-A1904** is an antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2), a tight junction protein selectively expressed in gastrointestinal cancers, linked with a cytotoxic payload to selectively kill cancer cells. The combination is currently under clinical investigation for synergistic anti-tumor activity in patients with advanced gastrointestinal cancers[3][5].